

1615#44
RECEIVED

PATENTS

JAN 10 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: F. Haviv, et al.

Serial NO.: 09/915,956

Filed: July 26, 2001

Title: PEPTIDES HAVING
ANTIANGIOGENIC ACTIVITY

Case No.: 6827.US.01



Group Art No.: 1615

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to it being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: December 20, 2001

Tanya Parent

Date

Assistant Commissioner for Patents
Washington D.C. 20231

Dear Sir:

TRANSMITTAL LETTER

Enclosed herewith for the patent application identified above entitled in PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, duplicate;
3. References as cited on PTO 1449 (33 references); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.



23492

ABBOTT LABORATORIES
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Respectfully submitted,
F. Haviv, et al.

Gregory W. Steele
Registration No. 33,796
Attorney for Applicants

TDS/ #4
JAN 10 2002

PATENT
TECH CENTER 1600

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: F. Haviv, et al.

Serial NO.: 09/915,956

Filed: July 26, 2001

Title: PEPTIDES HAVING
ANTIANGIOGENIC ACTIVITY

Case No.: 6827.US.01



Group Art No.: 1615

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: December 20, 2001

Tanya Parent 12/20/01
Tanya Parent Date

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.



23492

ABBOTT LABORATORIES
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Respectfully submitted,
F. Haviv, et al.


Gregory W. Steele
Registration No. 33,796
Attorney for Applicants

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6827.US.01	SERIAL NO. 09/915,956
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT F. Haviv et al.	
		FILING DATE July 26, 2001	GROUP 1615
(37 CFR 1.98 (b))		O P F JAN 08 2002 JC53 U.S. PATENT & TRADEMARK OFFICE	

RECEIVED
TECH CENTER 1600
JAN 10 2002
1600
2000

U.S.PATENT DOCUMENTS

EXAMINE R INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	A1	5 5 1 2 5 9 1	4/30/96	Halperin et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	B1	0 1 3 8 3 9 7		WO				
	B2	0 1 3 8 3 4 7		WO				
	B3	9 2 0 4 4 5 0	19.03.92	WO				
	B4	9 5 2 9 2 4 2	02.11.95	WO				
	B5	9 7 2 3 5 0 0	11.02.97	WO				
	B6	9 9 6 1 4 7 6		WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Fidler, I.J., et al., "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis", <i>Cell</i> , 79:185-188 (1994)
C2	Folkman et al., <i>J. Cancer Res.</i> 46:467-473 (1986)
C3	Folkman et al., <i>J. Natl. Cancer Inst.</i> 82:4-6 (1989)
C4	Folkman, J., "Clinical Applications of Research on Angiogenesis", <i>The New England Journal of Medicine</i> , 333(26):1757-1763 (1995)
C5	Folkman, J., et al., "Angiogenesis", <i>Journ. of Biological Chemistry</i> , 267(16):10931-10934 (1992)
C6	Folkman, J., et al., "Angiogenic Factors", <i>Science</i> , 235:442-447 (1987)
C7	Gasparini, G., et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool", <i>Journ. of Clinical Oncology</i> , 13(3):765-782 (1995)
C8	Kolberg, R., "Angogenic Inhibitor Loss May Be Key To Post-Surgery Metastasis", <i>Journal of NIH Research</i> , 8:31-33 (1994)
C9	McCane, S. et al., "Amino acid residues of the Kringle-4 and Kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands," <i>Journal of Biological Chemistry</i> 269:32405-32410 (1994)
C10	Mehart, N., et al., "Functional Independence of the Kringle 4 and Kringle 5 Regions of Human Plasminogen", <i>Biochemistry</i> , 32:8799-8806 (1993)
C11	Novokhatny, V. V., et al., "Domains in Human Plasminogen", <i>J. Mol. Biol.</i> , 179:215-232 (1984)
C12	O'Reilly, M. S., et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", <i>Cell</i> , 79:315-328 (1994)
C13	SCRIP 2120:21 (4/16/96)
C14	Sottrup-Jensen, L., et al., "The Primary Structure of Human Plasminogen: Isolation of Two Lysine-Binding Fragments and One "Mini-" Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", <i>Progress in Chemical Fibrinolysis and Thrombolysis</i> , 3:191-209 (1978)

RECEIVED
JAN 10 2002
TECH CENTER 6002

	C15	Teicher, B. A., <i>et al.</i> , "Influence of an Anti-Angiogenic Treatment on Gliosarcoma: Oxygenation and Response to Cytotoxic Therapy", <i>Int. J. Cancer</i> , 61 :732-737 (1995)
	C16	Teicher, B. A., <i>et al.</i> , "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents", <i>Int. J. Cancer</i> , 57 :920-925 (1994)
	C17	Teicher, B. A., <i>et al.</i> , "Antiangiogenic Agents Can Increase Tumor Oxygenation and Response to Radiation Therapy", <i>Radiation Oncology Investigations</i> , 2 :269-276 (1995)
JC53 3/14/08 2002 PATENT & TRADEMARK	C18	Teicher, B. A., <i>et al.</i> , "Antiangiogenic Agents Potentiate Cytotoxic Cancer Therapies against Primary and Metastatic Disease", <i>Cancer Research</i> , 52 :6702-6704 (1992)
JAN 10 2002 PATENT & TRADEMARK	C19	Teicher, B. A., <i>et al.</i> , "Antiangiogenic Treatment (TNP-470/Minocycline) Increases Tissue Levels of Anticancer Drugs in Mice Bearing Lewis Lung Carcinoma", <i>Oncology Research</i> , 7 (5):237-243 (1995)
	C20	Teicher, B. A., <i>et al.</i> , "Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMR-6 mammary carcinoma", <i>Breast Cancer Research and Treatment</i> , 36 :227-236 (1995)
	C21	Teicher, B. A., <i>et al.</i> , " β -Cyclodextrin tetradecasulfate/tetrahydrocortisol \pm minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic lewis lung carcinoma", <i>Cancer Chemother Pharmacol</i> , 33 :229-239 (1993)
	C22	Thewes, T. <i>et al.</i> , "Isolation, purification and 1H-NMR characterization of a kringle 5 domain fragment from human plasminogen," <i>Database Medline</i> , 1987
	C23	Thewest, T., <i>et al.</i> , "Ligand Interactions with the Kringle 5 Domain of Plasminogen", <i>Journal of Biological Chemistry</i> , 265 (7):3906-3915 (1990)
	C24	Tolsma <i>et al.</i> , <i>J. Cell Biol.</i> 122 :497-511 (1993)
	C25	Varadi, A. <i>et al.</i> , "Kringle 5 of human plasminogen carries a benzamidine-binding site," <i>Biochemical and Biophysical Research Communications</i> 103 :97-102 (1981)
	C26	Weidner, N., <i>et al.</i> , "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma", <i>The New England Journal of Medicine</i> , 324 (1):1-8 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)